Log in
Enquire now
‌

US Patent 10988546 BCMA monoclonal antibody-drug conjugate

Patent 10988546 was granted and assigned to MedImmune on April, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
MedImmune
MedImmune
Current Assignee
MedImmune
MedImmune
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10988546
Patent Inventor Names
Reena Varkey0
Xiaodong Xiao0
David Tice0
Elaine M. Hurt0
Krista Kinneer0
Date of Patent
April 27, 2021
Patent Application Number
16050944
Date Filed
July 31, 2018
Patent Citations Received
‌
US Patent 11912782 BCMA monoclonal antibody-drug conjugate
0
Patent Primary Examiner
‌
Lynn A Bristol
Patent abstract

The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10988546 BCMA monoclonal antibody-drug conjugate

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.